Navigation Links
Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
Date:1/7/2011

as CMV, herpes simplex virus and Epstein Barr virus, polyoma viruses such as BK virus and JC virus, and pox viruses.

Over 325 people have received CMX001 to date, including over 130 patients treated under Emergency INDs.  CMX001 has been well tolerated in all studies, with a growing body of evidence of the compound's antiviral activity in humans.  CMX001 is also being developed as a medical countermeasure in the event of a smallpox outbreak.  Chimerix has received significant funding from the National Institute of Allergy and Infectious Disease to develop CMX001 for smallpox.

Chimerix's second clinical-stage antiviral compound CMX157, a potent nucleoside analogue with activity against HIV and hepatitis B, is in development for the treatment of HIV infection including those caused by multi-drug resistant viruses.  CMX157 has completed Phase 1 clinical studies demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, suggesting the possibility of a convenient, once-weekly dosing regimen. CMX157's promising safety profile and efficient conversion to the active drug in PBMCs, coupled with the potent in vitro antiviral activity across diverse drug-resistant strains of HIV, indicate that this compound may directly address several limitations of current HIV therapies.

Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, malaria and other global public health needs.  For additional information on Chimerix, please visit http://www.chimerix.com.

(1) Code of Federal Regulations, Title 21, Revised April 2010


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
2. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
3. Chimerix to Present at Two Upcoming Investor Conferences
4. Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop
5. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
6. Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development
7. Chimerix to Present at 9th Annual BIO Investor Forum
8. Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent
9. Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
10. Chimerixs Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
11. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... HOUSTON , Oct. 22, 2014  Charlene Vernak, RPh, ... York , recently was awarded the George Roentsch ... Vernak received the award in Houston ... The scholarship is awarded annually to an independent pharmacist ... nature of George Roentsch , a well-known pharmacist ...
(Date:10/22/2014)... Oregon , October 22, 2014 ... "Global Disposable Gloves Market (Product type, Form, End user, ... Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and ... global disposable gloves market. Based on key trends tracked, ... be valued at $7.9 billion by 2020, registering a ...
(Date:10/22/2014)... , Oct. 21, 2014  Early symptoms ... subtle or unnoticed, but new technology, coupled with ... and leading to earlier detection of eye diseases, ... 29 million Americans. If left untreated, these diseases ... blindness. Recently, optometric researchers have ...
Breaking Medicine Technology:PCCA Awards Charlene Vernak, RPh, the George Roentsch Scholarship 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 3
... Delcath Systems, Inc. (Nasdaq: DCTH ), a developmental stage ... that it will open the NASDAQ stock market on Friday, ... Times Square in New York City will be broadcast ... NASDAQ webcam. The live ceremony, including President and Chief Executive Officer ...
... Inc. (Nasdaq: MYL ) today announced that it increased the ... pricing.  Mylan priced $550 million aggregate principal amount of ... and $700 million aggregate principal amount of 7.875% Senior ... to use approximately $1.0 billion of the net proceeds ...
Cached Medicine Technology:Delcath's Eamonn Hobbs to Ring NASDAQ Opening Bell 2Mylan Announces Upsizing and Pricing of Senior Notes 2Mylan Announces Upsizing and Pricing of Senior Notes 3
(Date:10/22/2014)... 2014 Isabel Healthcare will ... Professions (ASAHP) Conference on October 22-24 in Las Vegas, ... in a panel discussion on Technology in Health Professions ... provides a diagnostic decision support tool and clinical education ... of students and clinical learners. The Isabel tools help ...
(Date:10/22/2014)... The Louis W. Sullivan ... to distribute health information technology innovation to transform ... the development of six key guiding principles of ... healthcare. These are an expansion of the Institute ... that is respectful of and responsive to individual ...
(Date:10/22/2014)... Texas (PRWEB) October 22, 2014 ... of completing their continuing education at home or ... have access to 20 brand new, premium Seminar-on-Demand ... robust catalog of over 2,000 hours ... fully customize their educational experience. With such a ...
(Date:10/22/2014)... 22, 2014 Akeso Biomedical, Inc. ... the treatment of bacterial infections, microbial biofilms, and chronic ... its board of directors. , Dr. Sinskey ... at The Massachusetts Institute of Technology, or MIT. He ... 1968. Dr. Sinskey also holds positions as Co-Director of ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, 2014 ... fertilization (IVF) -- the incubation of embryos in a laboratory ... the vagina, new research suggests. Scientists from the United ... might sharply cut costs for pricey IVF procedures among certain ... those who don,t live near big-city assisted reproduction centers, the ...
Breaking Medicine News(10 mins):Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... , TONBRIDGE, England, Sept. ... innovation of the past 150 years, by leading figures in the ... the electric light bulb and penicillin in a star-studded competition organised ... The final four inventions went head-to-head in a live debate, with ...
... , , MIDDLETOWN, Conn., Sept. ... Blue Cross and Blue Shield Foundation grant to the national ... $37,500 to fund the "Family Link" program here in Connecticut. ... community-based network that connects parents of children with diabetes with ...
... , , ... (AFA) today applauded Senate Finance Committee Chairman Max Baucus (D-MT) ... including cognitive impairment screening for Medicare beneficiaries in Baucus, healthcare ... , , AFA had pressed for cognitive ...
... , , , MINNEAPOLIS, Sept. ... health by helping yogurt lovers regulate digestive health without compromising calorie ... Available in three delicious flavors -- Honey Vanilla, Strawberry Banana and ... Light is an easy way to help keep your digestive health ...
... , , , NEW YORK, Sept 17 ... today announced that it will host The Runyon 5K , ... on Sunday, November 15th 2009. Proceeds from the event, the first of ... scientists carrying out innovative research for all types of cancer. , ...
... Sept. 17, 2009 The Wellcome Trust and Merck ... MSD Wellcome Trust Hilleman Laboratories ( www.hillemanlaboratories.in ), the ... with a not-for-profit mission to focus on developing affordable ... The joint venture marks the first ...
Cached Medicine News:Health News:Contraceptive Pill Named the Greatest Pharmacy Invention of the Last 150 Years in Chemist+Druggist Competition 2Health News:Anthem Blue Cross and Blue Shield Foundation Grant Supporting American Diabetes Association's 'Family Link' Program In Connecticut 2Health News:Anthem Blue Cross and Blue Shield Foundation Grant Supporting American Diabetes Association's 'Family Link' Program In Connecticut 3Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Screening for Medicare Beneficiaries in Senate Finance Committee Health Reform Proposal 2Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Screening for Medicare Beneficiaries in Senate Finance Committee Health Reform Proposal 3Health News:Photos: New Yoplait(R) YoPlus(TM) Light... A Delicious Way to Regulate Digestive Health With Fewer Calories 2Health News:Photos: New Yoplait(R) YoPlus(TM) Light... A Delicious Way to Regulate Digestive Health With Fewer Calories 3Health News:Damon Runyon 5K Run/Walk at Yankee Stadium to Benefit Cancer Research 2Health News:Damon Runyon 5K Run/Walk at Yankee Stadium to Benefit Cancer Research 3Health News:Damon Runyon 5K Run/Walk at Yankee Stadium to Benefit Cancer Research 4Health News:Wellcome Trust and Merck launch joint venture to develop affordable vaccines 2Health News:Wellcome Trust and Merck launch joint venture to develop affordable vaccines 3Health News:Wellcome Trust and Merck launch joint venture to develop affordable vaccines 4
Anesthesia Associates Nerve Stimulator Model AA 1050...
... A range of easy to use instruments ... nerve locator, peripheral nerve stimulator, and muscle ... pole, plastic hub, and pencil point needles., ... inexpensive, practical and easy to use stimulator, ...
... nerve stimulator from B. Braun Medical. It ... stimulator functionality for over 10 years. , ... a unique, under-the-glove hand held remote current ... It allows the anesthesia provider operating solo ...
... the original MS-III design the ... enhanced keypad and ... MiniStim® MS-IV peripheral nerve stimulator ... monitoring in operating room, post ...
Medicine Products: